iBio (NYSE AMERICAN:IBIO) selected IBIO-201 as its leading candidate for the prevention of SARS-CoV-2 infection. iBio previously reported that both of its COVID-19 vaccine candidates, IBIO-200 and IBIO-201, in...
Spero Therapeutics (NASDAQ:SPRO) reported topline results from its Phase 3 ADAPT-PO trial evaluating tebipenem HBr for the treatment of complicated urinary tract infection (UTI) and acute pyelonephritis. Hospitalized...
Strongbridge Biopharma (NASDAQ:SBBP) reported topline data from its Phase 3 LOGICS trial evaluating RECORLEV for the treatment of endogenous Cushing’s syndrome. The study enrolled 44 patients to supplement the long-term...
Hepion Pharmaceuticals (NASDAQ:HEPA) reported that dosing has now been completed in all subjects enrolled in the Phase 1b multiple ascending dose (MAD) study of CRV431. The open-label MAD study was designed to assess...
iBio (NYSE AMERICAN:IBIO) entered into an exclusive worldwide license agreement with Planet Biotechnology for the development of Planet’s COVID-19 therapeutic candidate, ACE2-Fc. ACE2-Fc is a recombinant protein...
Durect (NASDAQ:DRRX) reported data from its Phase 2a trial evaluating DUR-928 for the treatment of alcoholic hepatitis at the liver congress. The dose escalation trial evaluated doses of 30 mg, 90 mg, or 150 mg of DUR...
Applied Molecular Transport (NASDAQ:AMTI) initiated its Phase 2a trial evaluating AMT-101 for the treatment of ulcerative colitis. The trial will enrol some 100 patients with moderate-to-severely active ulcerative...
IntelGenx (TSXV:IGX; OTCQB:IGXT) granted its partner, Exeltis Healthcare, an exclusive license to manufacture and commercialize RIZAPORT in the EU. Under the accord, Exeltis will pay IntelGenx royalties on net RIZAPORT...
Hepion Pharmaceuticals (NASDAQ:HEPA) will present a poster on CRV431’s antifibrotic activity at the Digital International Liver Congress 2020, taking place from Aug. 27-29. Dr. Joseph Kuo will present a preclinical...
Outlook Therapeutics (NASDAQ:OTLK) reported topline results from its Phase 2 NORSE 1 trial evaluating ONS-5010 for the treatment of wet age-related macular degeneration (AMD). The study, whose primary endpoint is the...